South Korea Medical Device Adverse Event Reporting: Obligations and Deadlines

1. Key takeaways

South Korea embeds the management duty for medical device adverse events directly in Article 31 (management of side effects) of the Medical Devices Act, without a separate dedicated statute: a medical device business operator that becomes aware of a death or a serious adverse event must report it to the Ministry of Food and Drug Safety (MFDS) and keep related records. The statutory duty-holder is the business operator, covering the entities actually carrying out manufacturing, import and distribution, not only the manufacturer itself.

• Three judgment points decide the internal division of work: the triggers are deaths and serious adverse events, while non-serious events are not exempt but enter a separate track of record keeping and periodic handling; reporting and record keeping are parallel obligations, and completing the report does not discharge the duty to retain documentation; foreign manufacturers do not report to MFDS in their own name — event information is consolidated and submitted by the Korean licence holder (KLH), as described in the guide on the KLH system.
• The most asked question, how many days a report is due, is answered in the legal text itself, not as a practical estimate. Article 31(1) requires immediate reporting and record keeping for deaths and serious side effects; Article 51(1) of the Enforcement Rule sets three tiers — death or life-threatening events within 7 days, details within 8 days of the first report date; hospitalisation or extended hospitalisation, irreversible severe disability or functional impairment, and congenital malformations within 15 days; other abnormal cases and foreign government measures within 30 days. The current notice is MFDS Notice No. 2026-67 (amended and effective September 22, 2026).

2. Legal basis

The obligations described in this guide rest on the following instruments, cited with document numbers, dates and provisions.

Note: the reporting periods are statutory figures fixed in Article 51(1) of the Enforcement Rule (7, 15 and 30 days, plus the 8-day detailed report window), so this guide does not treat them as a practical estimate; report forms and system operations follow MFDS Notice No. 2026-67 and the competent authority’s working requirements.

3. Expert insights

Insight 1: the duty attaches to business operator status, and foreign manufacturers often assume it does not concern them.

Article 31 names the medical device business operator as duty-holder, not the manufacturer. Licence holders in the import chain, distributors and lessors sit at different nodes of the information chain, and whoever receives event information first starts the clock. A typical GRZAN case: a manufacturer’s salesperson receives verbal physician feedback at a trade show, never passes it to the Korean licence holder, and it reaches compliance only at a quarterly review. Even if ultimately judged not reportable, the delay becomes an adverse fact in inspection.

Insight 2: turn the seriousness judgement into a company standard instead of waiting for the authority to classify the case.

What consumes time is not the submission but the judgement of whether an event is reportable. Death cases need almost no debate; deciding whether an event is a serious adverse event requires a written standard and an operating procedure. GRZAN recommends writing the judgement rules into the post-market management procedure and designating a single responsible person.

Insight 3: record keeping is a second obligation running parallel with reporting.

In self-inspections companies check whether something was reported but overlook whether records were kept by model. Article 31 states reporting and record keeping side by side: missing complete records is itself a non-conformity, regardless of actual harm. The trail should cover at least five points — occurrence, transmission of information, seriousness judgement, submission, and follow-up.

Insight 4: the reporting chain must reconcile with distribution records and recall data.

Adverse event handling often brings returns, disposal or recalls, and these flow into the category data of distribution record reporting, as described in the guide on distribution record reporting and supply details reporting. If the reporting position does not match the flow records in IMDIS, the authority cross-checks during re-evaluation or case inspections; conflicting data is harder to explain than a single delayed report.

Insight 5: the three tiers set internal judgement deadlines, not a uniform report-as-soon-as-possible rule.

Article 51(1) sets 7-day, 15-day and 30-day tiers by nature of the event, and requires details of death and life-threatening cases within 8 days of the first report. Work the tiers backwards into internal deadlines: the 7-day tier is tightest, so death or life-threatening information must enter judgement the day it is received; the 15-day tier covers hospitalisation, extended hospitalisation and permanent impairment, and congenital malformations; the 30-day tier covers other abnormal cases and foreign government measures. The first report of a death or life-threatening case need not be complete, but the 8-day window is a hard constraint — schedule investigation progress backwards from it rather than waiting for the investigation to close.

4. Practical recommendations

• Write the reporting chain into agreements before launch. Record in the KLH service agreement the notification deadline after event information arrives, who judges seriousness and who submits, instead of relying on informal email understanding.
• Keep a single event ledger, not parallel forms. Include at least six fields: receipt date, judgement date, conclusion, judgement-maker, submission date and archive location, so the chain can be demonstrated item by item during inspection.
• Make seriousness judgement a checklist rule. List situations that clearly must be reported plus a grey-zone list for collective review, treating every grey-zone case conservatively.
• Run a desktop exercise once a year. Walk a fictitious event through the full process to test the chain’s timeliness.
• Check the linkage with compensation liability insurance. Side-effect damages fall on the insurance line described in the guide on compensation liability insurance; re-review coverage as the product portfolio changes.
• Schedule internal milestones backwards from the three tiers. Death and life-threatening cases from 7 days with the 8-day detailed-report window reserved; hospitalisation-related and congenital malformation cases from 15 days; other abnormal cases and foreign government measures from 30 days. Mark each event’s tier and deadline in the ledger.

5. Verification checklist

• □ Duty-holder identification: verify business operator status of licence holders, distributors and lessors against Article 31; every node classified, no entity missed.
• □ Trigger condition list: written judgement rules for deaths and serious adverse events exist per Article 31, with a single responsible person designated.
• □ Reporting periods: each event classified into the 7-, 15- or 30-day tier under Article 51(1), with the 8-day detailed report of death or life-threatening cases on record; tiers and deadlines traceable.
• □ Submission route: licence holder submits on a consolidated basis with authorisation documents; the domestic entity does not submit to MFDS directly.
• □ Record keeping: sample the ledger and archives of the last 12 months; report and record sets complete and traceable to specific batches.
• □ Data consistency: cross-check event actions against IMDIS distribution and recall data; quantities and timing match, no contradictory declarations.
• □ Update mechanism: procedure revision dates checked against regulatory tracking; procedures revised within the defined cycle after the authority’s position changed.

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, Korean licence holder and local testing support for the Republic of Korea. Our team manages adverse event reporting and recall coordination with MFDS, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com